Security
Pelthos Therapeutics Inc. · PTHS
PTHSNYSE_AMERICANCommon stockCurrentCIK 1919246Updated Nov 2, 2026
Name history
Channel Therapeutics Corp · through May 27, 2025Chromocell Therapeutics Corp · through Nov 15, 2024
PTHS price & chart
Loading TradingView…
AMEX:PTHS on TradingView ↗About the company
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel, 10.3%, the Company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The Company’s portfolio of assets includes XEPI® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.
In the news
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes ↗
Recent filings
SCHEDULE 13D/A - filed by LIGAND PHARMACEUTICALS INC regarding Pelthos Therapeutics Inc.
425 filing
425 filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders · Regulation FD Disclosure
Items 1.01, 2.03, 3.02, 3.03, 5.02, 5.03, 5.07, 7.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 126,433,000Source | 2,139,888Source | 137,356,000Source | 822,850Source | 2,603,600Source | 145,378,000Source | 911,179Source | 4,031,559Source | 130,397,000Source | 1,369,143Source | 96,391Source | 55,074Source |
| Property, Plant and Equipment, NetUSD | 10,174,000Source | — | 8,881,000Source | — | — | 9,310,000Source | — | — | 9,586,000Source | — | — | — |
| GoodwillUSD | 30,625,000Source | — | 24,681,000Source | — | — | 24,681,000Source | — | — | 24,681,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 14,203,000Source | — | 24,192,000Source | 59,000Source | — | 31,976,000Source | 131,000Source | 3,800,000Source | 17,973,000Source | — | 100,000Source | 100,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 14,482,000Source | — | — | 11,700,000Source | — | — | 8,858,000Source | — | — | — |
| Inventory, NetUSD | 24,096,000Source | — | 21,472,000Source | — | — | 23,418,000Source | — | — | 23,574,000Source | — | — | — |
| Assets, CurrentUSD | 49,761,000Source | 2,139,888Source | 63,356,000Source | 822,850Source | 2,603,600Source | 69,801,000Source | 911,179Source | 4,031,559Source | 53,410,000Source | 1,369,143Source | 96,391Source | 55,074Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | 2,842,000Source | — | — | 2,457,000Source | — | — | 2,955,000Source | — | — | — |
| Operating Lease, Right-of-Use AssetUSD | 3,352,000Source | — | 3,041,000Source | — | — | 3,146,000Source | — | — | 3,250,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 68,180,000Source | 3,567,382Source | 138,857,000Source | 7,317,145Source | 2,786,121Source | 126,112,000Source | 5,107,013Source | 2,901,439Source | 91,516,000Source | 4,083,197Source | 6,540,943Source | 3,761,611Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | — | 583Source | 0Source | 67Source | 584Source | 0Source | 621Source | 578Source | 0Source | 613Source | 391Source | 111Source |
| Additional Paid in CapitalUSD | 101,383,000Source | 18,120,176Source | 109,705,000Source | 20,397,175Source | 17,670,493Source | 106,945,000Source | 19,246,143Source | 17,211,521Source | 103,675,000Source | 18,760,320Source | 7,074,646Source | 2,432,148Source |
| Retained Earnings (Accumulated Deficit)USD | -43,130,000Source | -19,548,253Source | -113,284,000Source | -26,891,537Source | -17,853,598Source | -89,867,000Source | -23,442,598Source | -16,081,979Source | -64,794,000Source | -21,474,987Source | -13,519,649Source | -6,138,856Source |
| Stockholders' Equity Attributable to ParentUSD | 58,253,000Source | -1,428,000Source | -1,501,000Source | -6,495,000Source | -182,521Source | 19,266,000Source | -4,196,000Source | 1,130,120Source | 38,881,000Source | -2,714,054Source | -6,444,552Source | -3,706,537Source |
| Liabilities and EquityUSD | 126,433,000Source | 2,139,888Source | 137,356,000Source | 822,850Source | 2,603,600Source | 145,378,000Source | 911,179Source | 4,031,559Source | 130,397,000Source | 1,369,143Source | 96,391Source | 55,074Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 24,768,000Source | 3,567,382Source | 31,959,000Source | 7,317,145Source | 2,786,121Source | 25,003,000Source | 5,107,013Source | 2,901,439Source | 25,993,000Source | 4,083,197Source | 6,540,943Source | 3,761,611Source |
| Operating Lease, Liability, CurrentUSD | 631,000Source | — | 645,000Source | — | — | 640,000Source | — | — | 635,000Source | — | — | — |
| Accounts Payable, CurrentUSD | 5,666,000Source | — | 5,853,000Source | — | — | 6,147,000Source | — | — | 2,986,000Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | — | — | 2,550,000Source | — | — | 2,652,000Source | — | — | 2,752,000Source | — | — | — |
| Other Liabilities, NoncurrentUSD | 26,175,000Source | — | — | — | — | 31,955,000Source | — | — | 30,050,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 11,890,000Source | 308Source | 20,745,000Source | 23,636Source | 363,429Source | 12,835,000Source | — | 493,924Source | 15,364,000Source | — | 645,947Source | 221,875Source |
| Intangible Assets, Net (Excluding Goodwill) | —Source | — | — | — | — | — | — | — | — | — | — | — |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Deferred Income Tax Liabilities, Net | —Source | — | — | — | — | — | — | — | — | — | — | — |
| Deferred Revenue, Current | —Source | — | — | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | —Source | — | —Source | —Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,908,000Source | 486,000Source | 5,461,000Source | 1,799,295Source | 1,733,233Source | 110,146Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 2,842,000Source | 0Source | 8,810,000Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -156,000Source | 0Source | -1,778,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 3,161,000Source | 707,000Source | 1,356,000Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -7,387,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -13,126,000Source | -632,000Source | -22,590,000Source | -5,792,483Source | -981,031Source | -1,567,149Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -194,000Source | 0Source | -5,236,000Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 194,000Source | 0Source | 99,000Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 75,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 27,523,000Source | 250,000Source | 45,336,000Source | 6,209,535Source | 1,022,348Source | 1,622,223Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 14,253,000Source | 1,255,000Source | — | 59,172Source | — | 131,317Source | — | 513,443Source | 96,391Source | 55,074Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 691,000Source | 0Source | 19,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | 1,077,000Source | 0Source | 2,397,000Source | — | — | — |
| AmortizationUSD | — | — | — | 395,419Source | — | 341,576Source | — | 403,921Source | — | 1,455,561Source | 1,733,233Source | 110,146Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 2,760,000Source | 394,000Source | 1,908,000Source | 456,000Source | 5,461,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | — | — | 679,000Source | — | 1,043,000Source | 0Source | 1,031,000Source | 0Source | 1,556,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | 278,000Source | 0Source | 469,000Source | 0Source | 729,000Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | 1,161,090Source | — | 1,110,084Source | — | 1,090,049Source | — | 4,110,045Source | 2,738,948Source | 1,098,848Source |
| GoodwillUSD | — | — | 30,625,000Source | — | 24,681,000Source | — | 24,681,000Source | — | 24,681,000Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 285,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | -465,000Source | — | 0Source | 0Source | 0Source | 0Source | -7,387,000Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | — | — | 2,389,000Source | 218,000Source | 2,353,000Source | 134,000Source | 3,012,000Source | — | — | — |
| Inventory Write-downUSD | — | — | — | — | 925,000Source | — | — | — | 1,055,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,238,000Source | -1,695,000Source | -23,417,000Source | -3,449,000Source | -25,073,000Source | -1,968,000Source | -43,319,000Source | -7,955,338Source | -7,380,793Source | -2,458,589Source |
| Nonoperating Income (Expense)USD | — | — | -1,341,000Source | 354,000Source | -6,094,000Source | -218,000Source | -11,985,000Source | -134,000Source | -18,276,000Source | -383,091Source | -518,509Source | -140,430Source |
| Operating ExpensesUSD | — | — | 22,768,000Source | 2,049,000Source | — | 3,230,423Source | — | 1,833,977Source | — | 7,571,449Source | 6,862,284Source | 2,318,159Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 165,000Source | — | 324,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 5,972,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 206,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 7,406,000Source | — | 15,603,000Source | 0Source | 10,906,000Source | 0Source | 16,795,000Source | — | — | — |
| Cost of RevenueUSD | — | — | 2,316,000Source | — | 3,610,000Source | 0Source | 1,673,000Source | 0Source | 3,988,000Source | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 19,628,000Source | 1,634,000Source | 27,673,000Source | 2,716,000Source | 21,104,000Source | 1,640,000Source | 42,453,000Source | — | — | — |
| Operating Income (Loss)USD | — | — | -15,362,000Source | -2,049,000Source | -17,323,000Source | -3,231,000Source | -13,088,000Source | -1,834,000Source | -32,430,000Source | -7,571,449Source | -6,862,284Source | -2,318,159Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -16,703,000Source | -1,695,000Source | -23,417,000Source | -3,449,000Source | -25,073,000Source | -1,968,000Source | -50,706,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | -465,000Source | — | 0Source | 0Source | 0Source | 0Source | -7,387,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,238,000Source | -1,695,000Source | -23,417,000Source | -3,449,000Source | -25,073,000Source | -1,968,000Source | -43,319,000Source | -7,955,338Source | -7,380,793Source | -2,458,589Source |
| Earnings Per Share, BasicUSD per share | — | — | -5.3Source | -2.93Source | -6.62Source | -5.29Source | -7.57Source | -3.21Source | -23.04Source | -1.43Source | 5.78Source | 5.65Source |
| Earnings Per Share, DilutedUSD per share | — | — | -5.3Source | -2.93Source | -6.62Source | -5.29Source | -7.57Source | -3.21Source | -23.04Source | -1.43Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 3,061,488Source | 579,229Source | 3,539,464Source | 651,921Source | 3,311,742Source | 612,889Source | 1,880,498Source | 5,574,473Source | 1,276,543Source | 435,312Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 3,061,488Source | 579,229Source | 3,539,464Source | 651,921Source | 3,311,742Source | 612,889Source | 1,880,498Source | 5,574,473Source | — | — |
| Interest Expense (non-operating)USD | — | — | — | — | 2,389,000Source | 218,000Source | 2,353,000Source | 134,000Source | 3,012,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 679,000Source | — | 1,043,000Source | 0Source | 1,031,000Source | 0Source | 1,556,000Source | — | — | — |
| Costs and ExpensesUSD | — | — | — | — | 32,926,000Source | 3,231,000Source | 23,994,000Source | 1,834,000Source | 49,225,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | 1,161,090Source | — | 1,110,084Source | — | 1,090,049Source | — | 4,110,045Source | 2,738,948Source | 1,098,848Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -50,231,000Source | — | — | — |
| Interest and Other IncomeUSD | — | — | — | — | — | — | — | — | 5,000Source | — | — | — |
| Interest Expense, DebtUSD | — | — | — | 0Source | — | — | — | — | — | 581,055Source | 14,370Source | 135,630Source |
| Nonoperating Income (Expense)USD | — | — | -1,341,000Source | 354,000Source | -6,094,000Source | -218,000Source | -11,985,000Source | -134,000Source | -18,276,000Source | -383,091Source | -518,509Source | -140,430Source |
| Operating ExpensesUSD | — | — | 22,768,000Source | 2,049,000Source | — | 3,230,423Source | — | 1,833,977Source | — | 7,571,449Source | 6,862,284Source | 2,318,159Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 165,000Source | — | 324,000Source | — | — | — |
| Other IncomeUSD | — | — | 5,000Source | 393,000Source | — | — | — | — | — | 39,413Source | — | — |
| Research and Development ExpenseUSD | — | — | 145,000Source | 415,000Source | 600,000Source | 515,000Source | 186,000Source | 194,000Source | 1,228,000Source | 1,179,436Source | 2,579,418Source | 391,730Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | —Source | —Source | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-293133
Filing attachments
tm2628523d2_ex4-2.htm · 425 · 2026-10-30
Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR (II) PURSUANT TO…
Read attachment ↗tm2628523d2_ex99-1.htm · 425 · 2026-10-30
Exhibit 99.1 Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary Platforms Across Therapeutic Modalities: Castle Creek’s Fibroblast-Based Cell and Gene Therapy Technology with Pelt…
Read attachment ↗tm2628523d1_ex4-2.htm · 8-K · 2026-10-30
Exhibit 4.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR (II) PURSUANT TO…
Read attachment ↗tm2628523d1_ex99-1.htm · 8-K · 2026-10-30
Exhibit 99.1 Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two Complementary Platforms Across Therapeutic Modalities: Castle Creek’s Fibroblast-Based Cell and Gene Therapy Technology with Pelt…
Read attachment ↗g085075_ex107.htm · S-3 · 2026-02-02
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) - Pelthos Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) N/A Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Amount Proposed Maximum Maximum Aggregate Fee Rate Amount of …
Read attachment ↗g085075_ex4-7.htm · S-3 · 2026-02-02
Exhibit 4.7 PELTHOS THERAPUETICS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ● ], 202[ ● ] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 1 DEFINITIONS ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗